ProShares UltraPro Short NASDAQ Biotechnology logo

ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) Q4 2024 Annual Earnings

ZBIO·Reported March 25, 2025·Before market open

ProShares UltraPro Short NASDAQ Biotechnology reported Q4 2024 revenue of $5.0M. Diluted EPS came in at $-3.99, missed the $-0.92 consensus by $3.07.

Revenue
$5.0M
Diluted EPS
$-3.99missed by $3.07
Consensus: $-0.92
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001558370-25-002631

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about ProShares UltraPro Short NASDAQ Biotechnology's Q4 2024 earnings report.

ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q4 2024 earnings on March 25, 2025 before market open.

ProShares UltraPro Short NASDAQ Biotechnology reported revenue of $5.0M and diluted EPS of $-3.99 for Q4 2024.

EPS missed the consensus estimate of $-0.92 by $3.07.

You can read the 10-K periodic report (0001558370-25-002631) directly on SEC EDGAR. The filing index links above go to sec.gov.